Proto Labs Inc (PRLB): restructuring charge — Proto Labs approves Germany facility closures; expects $4.5M-$6M restructuring charges

Proto Labs Inc

Plan closes prototype injection molding plant in Eschenlohe, Germany, and stops DMLS 3D printing in Putzbrunn.
Estimated total charges $4.5M-$6.0M including $2.5M-$3.5M severance and $2.0M-$2.5M asset write-downs.
Cash expenditures expected $3.0M-$4.0M; ~$4.0M charge expected in Q4 2024.
Substantial completion targeted within one year; European injection molding and metal 3D printing will continue via internal facilities and partners.
Affected German employees to receive severance and transition assistance meeting local requirements.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Proto Labs Inc announced a restructuring with charges of $4.5 million to $6.0 million affecting manufacturing facilities in Germany (Eschenlohe prototype injection molding facility; Putzbrunn 3D printing facility).

Type: restructuring
Charge: $4.5 million to $6.0 million
Affected area: manufacturing facilities in Germany (Eschenlohe prototype injection molding facility; Putzbrunn 3D printing facility)

Exact text from the filing

partners, consistent with the Company's recently announced global operations organization. The approved plan is expected to lead to total restructuring charges in the range of $4.5 million to $6.0 million, consisting of approximately $2.5 million to $3.5 million in severance and other employee-related costs, and $2.0 million to $2.5 million in fixed asset and

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Proto Labs Inc filing history →

Source: SEC EDGAR

accession 0001628280-24-043734

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.